BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35012940)

  • 1. Functional impact and targetability of
    Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
    Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
    Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
    Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
    Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
    Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
    Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
    Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
    J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Nakatani F; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Sep; 34(5):1569-1578. PubMed ID: 34164773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic and Molecular Study of an Adult Sclerosing Rhabdomyosarcoma of the Extremity:
    Gorunova L; Bjerkehagen B; Micci F; Heim S; Panagopoulos I
    Cancer Genomics Proteomics; 2020; 17(5):563-569. PubMed ID: 32859634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Role and Clinical Implications of
    Di Carlo D; Chisholm J; Kelsey A; Alaggio R; Bisogno G; Minard-Colin V; Jenney M; Dávila Fajardo R; Merks JHM; Shipley JM; Selfe JL
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
    Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
    Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: Functional impact and targetability of
    Choo F; Odintsov I; Nusser K; Nicholson K; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483883
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
    Rekhi B; Dodd L; Dharavath B; Dutt A
    Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile.
    Schleicher S; Grote S; Malenke E; Chan KC; Schaller M; Fehrenbacher B; Riester R; Kluba T; Frauenfeld L; Boesmueller H; Göhring G; Schlegelberger B; Handgretinger R; Kopp HG; Traub F; Boehme KA
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived spindle-cell/sclerosing rhabdomyosarcoma cell line.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Sugaya J; Iwata S; Sugiyama M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Jul; 33(3):886-893. PubMed ID: 32300959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
    Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.